Adverum Biotechnologies (ADVM) Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Adverum Biotechnologies (ADVM) Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD

Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter

August 10, 2020 4:00 PM EDT

-- Continued robust treatment response from both high and low doses --

-- Long-term durability beyond 15 months from single IVT injection with zero rescue injections in Cohort 1 --

-- Well tolerated across all Cohorts; encouraging early safety data from Cohort 4 --

-- OPTIC enrollment complete; planning to start pivotal trial in wet AMD mid-2021 --

-- Company to host conference call and webcast with Key Opinion Leader Dr. Arshad Khanani today at 1:30 pm PT / 4:30 pm ET --

... More